The effect of S-adenosyl-L-methionine and antihypertensive combination treatment on the comorbid course of metabolic-associated steatotic liver disease and arterial hypertension

Abstract

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), defined by a broad spectrum of liver damage ranging from simple steatosis to progressive nonalcoholic steatohepatitis (NASH), liver fibrosis (LF), and cirrhosis, is increasing every year in patients with obesity and other metabolic syndromes. Recently, the study of the mechanisms of MASLD progression in patients with concomitant arterial hypertension (AH) has attracted considerable attention from scientists. AH is a multifactorial disease that results from the interaction between genetic predisposition and environmental risk factors. The main reason for the increased mortality of patients with MASLD and AH is the development of cardiovascular diseases. Currently, the mechanisms of drug correction of this comorbid pathology remain poorly understood. Therefore, the search for effective treatment regimens for patients with combined MASLD and AH is a relevant issue of modern internal medicine